As shown in Fig 9, trastuzumab and fulvestrant, either as single agents or in combination decreased the levels of the p-MED1 (phosphorylated MED1) protein expressed in ZR-75-1 tumor xenografts (P<0.001 for all the treatment groups compared with vehicle-treated group), and simultaneously increased expression levels of total MED1 protein (Tras vs. vehicle, P<0.001; Ful vs. vehicle, P = 0.011; Com vs. vehicle, P = 0.010). This evidence concerns the gene MED1 and neoplasm.